Original Article

You have full text access to this OnlineOpen article

Comparison of intravenous and intramuscular neridronate regimens for the treatment of paget disease of bone

  1. Daniela Merlotti1,*,
  2. Domenico Rendina2,
  3. Luigi Gennari1,
  4. Giuseppe Mossetti2,
  5. Fernando Gianfrancesco3,
  6. Giuseppe Martini1,
  7. Gianpaolo De Filippo2,
  8. Annalisa Avanzati1,
  9. Beatrice Franci1,
  10. Maria Stella Campagna1,
  11. Pasquale Strazzullo2,
  12. Ranuccio Nuti1

Article first published online: 18 FEB 2011

DOI: 10.1002/jbmr.237

Issue

Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

Volume 26, Issue 3, pages 512–518, March 2011

Additional Information

How to Cite

Merlotti, D., Rendina, D., Gennari, L., Mossetti, G., Gianfrancesco, F., Martini, G., De Filippo, G., Avanzati, A., Franci, B., Campagna, M. S., Strazzullo, P. and Nuti, R. (2011), Comparison of intravenous and intramuscular neridronate regimens for the treatment of paget disease of bone. J Bone Miner Res, 26: 512–518. doi: 10.1002/jbmr.237

Author Information

  1. 1

    Department of Internal Medicine, Endocrine-Metabolic Sciences, and Biochemistry, University of Siena, Italy

  2. 2

    Department of Clinical and Experimental Medicine, Federico II University Medical School, Naples, Italy

  3. 3

    Institute of Genetics and Biophysics “Adriano Buzzati-Traverso,” Italian National Research Council, Naples, Italy

*Department of Internal Medicine, Endocrine-Metabolic Sciences, and Biochemistry, University of Siena, Viale Bracci 1, 53100 Siena, Italy.

Publication History

  1. Issue published online: 18 FEB 2011
  2. Article first published online: 18 FEB 2011
  3. Accepted manuscript online: 2 SEP 2010 03:07PM EST
  4. Manuscript Accepted: 24 AUG 2010
  5. Manuscript Revised: 24 JUN 2010
  6. Manuscript Received: 30 APR 2010

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (193K)

References

  • 1
    Paget J. On a form of chronic inflammation of bones (osteitis deformans). Med Chir Trans. 1877; 60: 37–63.
  • 2
    Altman RD. Paget disease of bone. In: Coe FL, Favus MJ, eds. Disorders of Bone and Mineral Metabolism. New York: Raven Press, 1991; 1027–1064.
  • 3
    Cooper C, Harvey NC, Dennison EM, van Staa TP. Update on the epidemiology of Paget disease of bone. J Bone Miner Res. 2006; 21: P3–8.
    Direct Link:
  • 4
    van Staa TP, Selby P, Leufkens HG, Lyles K, Sprafka JM, Cooper C. Incidence and natural history of Paget disease of bone in England and Wales. J Bone Miner Res. 2002; 17: 465–471.
    Direct Link:
  • 5
    Gold DT, Boisture J, Shipp KM, Pieper CF, Lyles KW. Paget's disease of bone and quality of life. J Bone Miner Res. 1996; 11: 1897–1904.
    Direct Link:
  • 6
    Selby PL, Davie MWJ, Ralston SH, Stone MD. Guidelines on the management of Paget's disease of bone. Bone. 2002; 31: 10–19.
  • 7
    Merlotti D, Gennari L, Martini G, Nuti R. Current options for the treatment of Paget's disease of the bone. Open Access Rheumatology Research and Reviews. 2009; 1: 107–120.
  • 8
    Gennari L, Merlotti D, Mossetti G, et al. The use of intravenous aminobisphosphonates for the treatment of Paget's disease of bone. Mini Rev Med Chem. 2009; 9: 1052–1063.
  • 9
    Papapoulos SE, Eekhoff EM, Zwinderman AH. Acquired Resistance to Bisphosphonates in Paget's Disease of Bone. J Bone Miner Res. 2006; 21: P88–P91.
    Direct Link:
  • 10
    Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001; 296: 235–242.
  • 11
    Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006; 38: 617–627.
  • 12
    Papapoulos SE. Bisphosphonate actions: physical chemistry revisited. Bone. 2006; 38: 613–616.
  • 13
    Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006; 81: 1013–1022.
  • 14
    Walsh JP, Attewell R, Stuckey BGA, et al. Treatment of Paget disease of bone: A survey of clinical practice in Australia. Bone. 2008; 42: 1219–1225.
  • 15
    Merlotti D, Gennari L, Martini G, et al. Comparison of Different Intravenous Bisphosphonate Regimens for Paget Disease of Bone. J Bone Miner Res. 2007; 22: 1510–1517.
    Direct Link:
  • 16
    Tong D, Gillick L, Hendrickson FR. The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group. Cancer. 1982; 50: 893–899.
    Direct Link:
  • 17
    Rendina D, Mossetti G, Viceconti R, Sorrentino M, Nunziata V. Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates. Calcif Tissue Int. 2004; 75: 189–196.
  • 18
    Gutteridge DH, Ward LC, Stewart GO, et al. Paget's disease: acquired resistance to one aminobisphosphonate with retained response to another. J Bone Miner Res. 1999; 14: 79–84.
  • 19
    Trombetti A, Arlot M, Thevenon J, Uebelhart B, Meunier PJ. Effect of multiple intravenous pamidronate courses in Paget disease of bone. Rev Rhum (Engl Ed). 1999; 66: 467–476.
  • 20
    Atkins RM, Yates AJ, Gray RE, et al. Aminohexane bisphosphonate in the treatment of Paget disease of bone. J Bone Miner Res. 1987; 2: 273–2799.
    Direct Link:
  • 21
    Delmas P, Chapuy MC, Edouard C, Meunier PJ. Beneficial effects of aminohexane bisphosphonate in patients with Paget disease of bone resistant to sodium etidronate. Am J Med. 1987; 83: 276–282.
  • 22
    Filipponi P, Cristallini S, Policani G, Casciari C, Gregorio F. Paget disease of bone: benefits of neridronate as a first treatment and in cases of relapse after clodronate. Bone. 1998; 23: 543–548.
  • 23
    Fleisch H. Bisphosphonates: mechanism of action. Endocrine Rev. 1998; 19: 80–100.
  • 24
    Neves M, Gano L, Pereira N, et al. Synthesis, characterization and biodistribution of bisphosphonates Sm-153 complexes: correlation with molecular modeling interaction studies. Nuclear Medicine and Biology. 2002; 29: 329–338.
  • 25
    Adami S, Bevilacqua M, Broggini M, et al. Short-term intravenous therapy with Neridronate in Paget disease. Clin Exp Rheumatol. 2002; 20: 55–58.
  • 26
    Adami S, Gatti D, Bertoldo F, et al. Intramuscular neridronate in postmenopausal women with low bone mineral density. Calcif Tissue Int. 2008; 83: 301–307.
  • 27
    Bertoldo F, Pancheri S, Zenari S, et al. Serum 25(OH)D levels modulate the acute phase response associated to the first nitrogen containing bisphosphonate infusion. J Bone Miner Res. 2010; 25: 447–454.
    Direct Link:
  • 28
    Chen L, Cencioni MT, Angelini DF, Borsellino G, Battistini L, Brosnan CF. Transcriptional profiling of gamma-delta T cells identifies a role for vitamin D in the immunoregulation of the Vgamma9Vdelta2 response to phosphonate-containing ligands. J Immunol. 2005; 174: 6144–6152.
  • 29
    Deane A, Constancio L, Fogelman I, Hampson G. The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis. BMC Musculoskelet Disord. 2007; 8: 3.
  • 30
    Geller JL, Hu B, Reed S, Mirocha J, Adams JS. Increase in bone mass after correction of vitamin D insufficiency in bisphosphonate-treated patients. Endocr Pract. 2008; 14: 293–297.
  • 31
    Barone A, Giusti A, Pioli G, et al. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial. J Am Geriatr Soc. 2007; 55: 752–757.
    Direct Link:
  • 32
    Adami S, Giannini S, Bianchi G, et al. Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int. 2009; 20: 239–244.
View Full Article (HTML) Get PDF (193K)